Current progress towards the development of tyrosine kinase inhibitors as anticancer agents

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.3, Iss.1, 1998-06, pp. : 279-292

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas Cherrington Julie M

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite

Protein tyrosine kinase inhibitors as anticancer agents

By Supuran Claudiu T Scozzafava Andrea

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 1, 2004-01 ,pp. : 35-53

Informa Healthcare

Access to resources Recommend Favorite

Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents

Current Cancer Drug Targets, Vol. 1, Iss. 2, 2001-08 ,pp. : 129-140

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents

Current Medicinal Chemistry, Vol. 22, Iss. 2, 2014-12 ,pp. : 237-263

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents

Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 10, 2008-09 ,pp. : 1053-1063

Bentham Science Publishers

Access to resources Recommend Favorite